Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Megakaryocyte Engineering to Create Designer Platelets
FY 2018-19
Summary
Platelets are small circulating cells that act as natural delivery vehicles for numerous small molecules and regulate many physiological processes such as blood clotting, immune function, and cancers. Platelets are often transfused to help stop bleeding, but their application in other diseases is limited by challenges to modify and enhance platelet function for therapeutic purposes. For example, there are currently no methods to modify the protein content of transfusable platelets. This project therefore aims to develop novel approaches to engineer platelets by modifying their precursor cells, megakaryocytes (MKs). This will be achieved by using lipid nanoparticles (LNPs)—a recently FDA-approved drug delivery vehicle—targeted to MKs, delivering nucleic acids to alter the protein composition of platelets. Successful implementation of this strategy will therefore create a platform technology to produce platelets with new and modified functions that current transfused platelets do not possess. The technology will enable platelets to locally deliver therapeutics to injured tissues, such as sites of trauma, or potentially to treat diseased tissues and organs where platelets accumulate, such as tumours or the brain for treating Alzheimer’s disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406298
Name
Leung Jerry
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Megakaryocyte Engineering to Create Designer Platelets
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Targeting; Cell Therapy; Lipid Nanoparticles; Megakaryocyte Engineering; Nucleic Acid Delivery; Platelet Disorders; Platelet Engineering; Platelet Transfusion; Thrombosis; Trauma
Abstract
Platelets are small circulating cells that act as natural delivery vehicles for numerous small molecules and regulate many physiological processes such as blood clotting, immune function, and cancers. Platelets are often transfused to help stop bleeding, but their application in other diseases is limited by challenges to modify and enhance platelet function for therapeutic purposes. For example, there are currently no methods to modify the protein content of transfusable platelets. This project therefore aims to develop novel approaches to engineer platelets by modifying their precursor cells, megakaryocytes (MKs). This will be achieved by using lipid nanoparticles (LNPs)—a recently FDA-approved drug delivery vehicle—targeted to MKs, delivering nucleic acids to alter the protein composition of platelets. Successful implementation of this strategy will therefore create a platform technology to produce platelets with new and modified functions that current transfused platelets do not possess. The technology will enable platelets to locally deliver therapeutics to injured tissues, such as sites of trauma, or potentially to treat diseased tissues and organs where platelets accumulate, such as tumours or the brain for treating Alzheimer’s disease.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leung, Jerry
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~